Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin in Diabetic Nephropathy
NCT06031389Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in diabetic nephropathy (DN) comparing Henagliflozin Arm with Placebo Arm (2 arms). Primary endpoint: Intestinal flora difference by 16srDNA sequencing at 12 months. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT06031389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031389.